Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2024-08-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于恩威医药股份有限公司部分募集资金投资项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the delay in certain investment projects funded by raised capital for Enwei Pharmaceutical Co., Ltd. It includes specifics about the capital raised, usage plans, adjustments to investment amounts, project progress, reasons for delays, and approvals by the board and supervisory committee. The content focuses on the management and use of raised funds, project timelines, and compliance with regulatory requirements related to capital usage. This aligns with the category of Capital/Financing Update (CAP), as it provides an update on the use and adjustment of raised capital investment projects, rather than a full financial report or an announcement of a report publication. The document length (3868 characters) is sufficient to contain substantive information, not just a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2024-08-29 Chinese
2024年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2024. It includes specific financial figures such as beginning balances, cumulative amounts, interest, repayments, and ending balances related to non-operating funds and related party transactions. The presence of half-year period data and substantive financial details indicates this is a financial report for a period shorter than a full fiscal year. There is no indication that this is an announcement or a certification, nor is it a full annual report or an earnings release. The document fits the definition of an Interim / Quarterly Report (IR) as it contains comprehensive financial data for a half-year period. H1 2024
2024-08-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the third meeting of the third Supervisory Board of Enwei Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results on several agenda items such as approval of the 2024 semi-annual report, a special report on the use of raised funds, an extension of investment projects, and the establishment of an internal audit system. The document is an official announcement of meeting decisions rather than the report itself. It is short (1212 characters) and does not contain the full semi-annual report or detailed financial statements. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and disclosures that do not fit other categories.
2024-08-29 Chinese
关于举行2024年半年度网上业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling of a 2024 half-year online earnings presentation by the company, including details on how investors can participate and submit questions. It does not contain actual financial data or results but rather invites investors to attend the event where such information will be discussed. The document length is short (677 characters) and it is clearly an announcement of an upcoming event rather than the event transcript or financial report itself. Therefore, it fits best as an Investor Presentation (IP) announcement or possibly a Call Transcript (CT) if it were the transcript, but since it is only announcing the event, it is closest to an Investor Presentation (IP) type document.
2024-08-29 Chinese
内部审计制度
Audit Report / Information Classification · 95% confidence The document is titled '内部审计制度' (Internal Audit System) of 恩威医药股份有限公司 and details the internal audit policies, responsibilities, procedures, and organizational structure. It references relevant laws and regulations, internal control evaluation, audit committee roles, and reporting requirements. The content is a comprehensive internal audit policy document rather than an audit report or financial statement. It does not contain actual financial data or audit results but rather the framework and rules governing internal audit activities. Therefore, it is best classified as an Audit Report / Information (AR) type, which includes applied accounting principles and internal audit system information, excluding full annual reports or standalone financial statements. The document length (6769 characters) supports it being a substantive policy document rather than a brief announcement or certification. FY 2024
2024-08-29 Chinese
关于子公司收到《接受跨省受托生产事项审查意见》的自愿性披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Enwei Pharmaceutical Co., Ltd. regarding its subsidiary receiving a review opinion from the Sichuan Provincial Drug Administration about cross-province entrusted production matters. It details the approval process, the products involved, and the regulatory steps taken. The document is short (1318 characters), does not contain financial statements or detailed financial data, and is primarily an operational and regulatory update. It is not a financial report, earnings release, or management report. It is also not a regulatory certification or officer attestation. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about compliance and operational approvals that does not fit other specific categories.
2024-08-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.